8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
A detailed clinical review of BPC-157 pharmacogenomics in patients of Black and African ancestry, covering ACE pathway interactions, G6PD prevalence, CKD risk overlap, and what is known, and unknown, about ethnicity-stratified efficacy data.
A deep clinical review of BPC-157 efficacy differences in East Asian patients, covering CYP2C19/CYP2D6 polymorphisms, BMI-adjusted dosing, and the current state of ethnicity-stratified trial data.
A guide to BPC-157 dosing in East Asian patients, covering CYP2C19/CYP2D6 polymorphism frequencies, lower BMI thresholds, HLA risk context, and ethnicity-specific starting doses.
A clinical review of BPC-157 dosing for Hispanic and Latino patients, covering pharmacogenomics, diabetes-related considerations, CYP variant data, and practical prescribing guidance prepared by the HealthRX.com Editorial Team.
Evidence review of BPC-157 pentadecapeptide efficacy in South Asian populations, covering pharmacogenomic variability, dosing considerations, and documented gaps in ethnicity-stratified clinical data.
BPC-157 pentadecapeptide lacks ethnicity-stratified human trial data. This article covers pharmacogenomic factors, G6PD considerations, renal risk, and monitoring guidance for Black / African ancestry patients considering BPC-157.
Evidence-based review of BPC-157 pentadecapeptide safety considerations for South Asian individuals, including pharmacogenomic factors, cardiovascular risk at lower BMI thresholds, and dosing guidance.
A guide to BPC-157 dosing in South Asian patients, covering pharmacogenomics, cardiovascular risk context, metabolic differences, and evidence-based adjustment frameworks.